A phase 3 trial of Intellia Therapeutics’ in vivo gene editing therapy lonvoguran ziclumeran (lonvo-z) has hit its primary ...
Jazz Pharmaceuticals recently announced that it and its partners will present three rapid oral and seven poster oncology data sets at the 2026 ASCO Annual Meeting in Chicago, including Phase 3 results ...
Intellia Therapeutics (NASDAQ:NTLA) highlighted top-line results from its Phase III HAELO trial evaluating lonvo-z, an ...
The high-priority National Security Space Launch Phase 3 missions include six launches in FY2027, nine in FY2028 and 10 in ...
InvestorsHub on MSN
Intellia Therapeutics shares slip despite strong phase 3 data
Intellia Therapeutics Inc. (NASDAQ:NTLA) declined 3% on Monday, reversing earlier gains that followed the release of positive ...
Intellia (NTLA) stock dropped 3% despite positive Phase 3 results showing 87% attack reduction. FDA submission underway with ...
AstraZeneca’s chronic obstructive pulmonary disease (COPD) candidate has served up a third phase 3 win this year, offering ...
Phase 3 HAELO trial of lonvoguran ziclumeran (lonvo-z) met primary and all key secondary endpoints; favorable safety and ...
Tozorakimab is an investigational monoclonal antibody designed to bind and inhibit interleukin-33 (IL-33), an alarmin cytokine. This targeted approach is expected to reduce airway inflammation and ...
Alignment reached on chemistry, manufacturing, and control (CMC) elements of ATH434 Phase 3 development program - - Positive feedback supports readiness for Phase 3 initiation with manufacturing scale ...
Zasocitinib showed superiority over placebo in phase 3 trials, achieving rapid and sustained skin clearance in plaque psoriasis. The trials demonstrated a favorable safety profile, with common adverse ...
Intellia Therapeutics’ CRISPR-based therapy lonvoguran ziclumeran reduced hereditary angioedema attacks by 87% in a pivotal ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results